Acute humoral rejection in pediatric renal transplant recipients receiving steroid minimization immunosuppression

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

SM protocols have increasingly gained acceptance owing to their favorable side effect profile with comparable cellular rejection rates. After encountering SM patients with AHR, we performed a case-control study to identify predictors associated with AHR in this cohort. Patients with (n = 4) and without (n = 19) biopsy proven AHR on a SM regimen were compared using the Student's t-tests. The median age at transplant was 13.8 yr. Compared to controls, the AHR cohort was older (15.9 vs. 12.1 yr, p = 0.01). Children with AHR had a lower mean tacrolimus trough level and were more likely to have a sub-therapeutic trough at six months (3.5 vs. 5.5 ng/mL, p = 0.05); mean MMF doses were lower at all times points except three months in the AHR group (not statistically significant). This occurred in spite of higher MPA trough levels at all study points in the AHR group (significant at 3 [p = 0.019] and 6 [p = 0.03] months). Children receiving a SM regimen have a lower safety net and may benefit from more intensive monitoring of tacrolimus exposure. MMF dose modifications based on MPA trough determinations should be resisted in the setting of SM.

Original languageEnglish (US)
Pages (from-to)269-273
Number of pages5
JournalPediatric Transplantation
Volume16
Issue number3
DOIs
StatePublished - May 2012

Fingerprint

Tacrolimus
Immunosuppression
Steroids
Pediatrics
Kidney
Case-Control Studies
Students
Transplants
Biopsy
Safety
Transplant Recipients
Therapeutics

Keywords

  • acute humoral rejection
  • donor-specific antibodies
  • steroid discontinuation

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Transplantation

Cite this

@article{0c6704ffa423488f91cb2394c04d6389,
title = "Acute humoral rejection in pediatric renal transplant recipients receiving steroid minimization immunosuppression",
abstract = "SM protocols have increasingly gained acceptance owing to their favorable side effect profile with comparable cellular rejection rates. After encountering SM patients with AHR, we performed a case-control study to identify predictors associated with AHR in this cohort. Patients with (n = 4) and without (n = 19) biopsy proven AHR on a SM regimen were compared using the Student's t-tests. The median age at transplant was 13.8 yr. Compared to controls, the AHR cohort was older (15.9 vs. 12.1 yr, p = 0.01). Children with AHR had a lower mean tacrolimus trough level and were more likely to have a sub-therapeutic trough at six months (3.5 vs. 5.5 ng/mL, p = 0.05); mean MMF doses were lower at all times points except three months in the AHR group (not statistically significant). This occurred in spite of higher MPA trough levels at all study points in the AHR group (significant at 3 [p = 0.019] and 6 [p = 0.03] months). Children receiving a SM regimen have a lower safety net and may benefit from more intensive monitoring of tacrolimus exposure. MMF dose modifications based on MPA trough determinations should be resisted in the setting of SM.",
keywords = "acute humoral rejection, donor-specific antibodies, steroid discontinuation",
author = "Lavjay Butani and Gallay, {Brian J}",
year = "2012",
month = "5",
doi = "10.1111/j.1399-3046.2011.01618.x",
language = "English (US)",
volume = "16",
pages = "269--273",
journal = "Pediatric Transplantation",
issn = "1397-3142",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Acute humoral rejection in pediatric renal transplant recipients receiving steroid minimization immunosuppression

AU - Butani, Lavjay

AU - Gallay, Brian J

PY - 2012/5

Y1 - 2012/5

N2 - SM protocols have increasingly gained acceptance owing to their favorable side effect profile with comparable cellular rejection rates. After encountering SM patients with AHR, we performed a case-control study to identify predictors associated with AHR in this cohort. Patients with (n = 4) and without (n = 19) biopsy proven AHR on a SM regimen were compared using the Student's t-tests. The median age at transplant was 13.8 yr. Compared to controls, the AHR cohort was older (15.9 vs. 12.1 yr, p = 0.01). Children with AHR had a lower mean tacrolimus trough level and were more likely to have a sub-therapeutic trough at six months (3.5 vs. 5.5 ng/mL, p = 0.05); mean MMF doses were lower at all times points except three months in the AHR group (not statistically significant). This occurred in spite of higher MPA trough levels at all study points in the AHR group (significant at 3 [p = 0.019] and 6 [p = 0.03] months). Children receiving a SM regimen have a lower safety net and may benefit from more intensive monitoring of tacrolimus exposure. MMF dose modifications based on MPA trough determinations should be resisted in the setting of SM.

AB - SM protocols have increasingly gained acceptance owing to their favorable side effect profile with comparable cellular rejection rates. After encountering SM patients with AHR, we performed a case-control study to identify predictors associated with AHR in this cohort. Patients with (n = 4) and without (n = 19) biopsy proven AHR on a SM regimen were compared using the Student's t-tests. The median age at transplant was 13.8 yr. Compared to controls, the AHR cohort was older (15.9 vs. 12.1 yr, p = 0.01). Children with AHR had a lower mean tacrolimus trough level and were more likely to have a sub-therapeutic trough at six months (3.5 vs. 5.5 ng/mL, p = 0.05); mean MMF doses were lower at all times points except three months in the AHR group (not statistically significant). This occurred in spite of higher MPA trough levels at all study points in the AHR group (significant at 3 [p = 0.019] and 6 [p = 0.03] months). Children receiving a SM regimen have a lower safety net and may benefit from more intensive monitoring of tacrolimus exposure. MMF dose modifications based on MPA trough determinations should be resisted in the setting of SM.

KW - acute humoral rejection

KW - donor-specific antibodies

KW - steroid discontinuation

UR - http://www.scopus.com/inward/record.url?scp=84859730837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859730837&partnerID=8YFLogxK

U2 - 10.1111/j.1399-3046.2011.01618.x

DO - 10.1111/j.1399-3046.2011.01618.x

M3 - Article

VL - 16

SP - 269

EP - 273

JO - Pediatric Transplantation

JF - Pediatric Transplantation

SN - 1397-3142

IS - 3

ER -